Racial Differences in Disease Activity and Quality of Life in Patients with Crohn’s Disease

[1] Loftus EV(2004)Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences Gastroenterology 126 1504-1517

[2] Colombel JF(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[3] Sandborn WJ(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial Lancet 359 1541-1549

[4] Rutgeerts P(2007)Certolizumab pegol for the treatment of Crohn’s disease N Engl J Med 357 228-238

[5] Sandborn WJ(2006)Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database Am J Gastroenterol 101 1274-1282

[6] Feagan BG(2005)Impact of race and ethnicity on inflammatory bowel disease Am J Gastroenterol 100 2254-2261

[7] Stoinov S(2006)Racial differences in disease phenotype in patients with Crohn’s disease Inflamm Bowel Dis 12 192-198

[8] Basu S(2008)Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study Inflamm Bowel Dis 14 13-19

[9] Lopez I(2008)Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study Dig Dis Sci 53 2754-2760

[10] Kulkarni A(2006)Inflammatory bowel disease characteristics among African Americans, Hispanics, and Non-Hispanic Whites: characterization of a large North American cohort Am J Gastroenterol 101 1012-1023

[1] Loftus EV(2004)Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences Gastroenterology 126 1504-1517

[2] Colombel JF(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65

[3] Sandborn WJ(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial Lancet 359 1541-1549

[4] Rutgeerts P(2007)Certolizumab pegol for the treatment of Crohn’s disease N Engl J Med 357 228-238

[5] Sandborn WJ(2006)Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database Am J Gastroenterol 101 1274-1282

[6] Feagan BG(2005)Impact of race and ethnicity on inflammatory bowel disease Am J Gastroenterol 100 2254-2261

[7] Stoinov S(2006)Racial differences in disease phenotype in patients with Crohn’s disease Inflamm Bowel Dis 12 192-198

[8] Basu S(2008)Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study Inflamm Bowel Dis 14 13-19

[9] Lopez I(2008)Racial differences in disease extent and severity in patients with ulcerative colitis: a retrospective cohort study Dig Dis Sci 53 2754-2760

[10] Kulkarni A(2006)Inflammatory bowel disease characteristics among African Americans, Hispanics, and Non-Hispanic Whites: characterization of a large North American cohort Am J Gastroenterol 101 1012-1023